Table S3: Association of ADMA Categorized and Outcomes in the HEMO Study

					Model 1		Model 2		Model 3		Model 4	
	Range, μM	**N**	**Events**	**IR Per 1000 PY**	**HR (95% CI)**	***P***	**HR (95% CI)**	***P***	**HR (95% CI)**	***P***	**HR (95% CI)**	***P***
Cardiac Death												
ADMA												
Quintile 1 to 4	0.43-1.06	1018	154	57.6	Reference		Reference		Reference		Reference	
Quintile 5	1.07-2.56	258	66	108.8	**1.96 (1.48-2.59)**	**<.001**	**2.04 (1.55-2.68)**	**<.001**	**1.78 (1.36-2.31)**	**<.001**	**1.76 (1.34-2.31)**	**<.001**
Sudden Cardiac Death												
ADMA												
Quintile 1 to 4	0.43-1.06	1018	87	32.5	Reference		Reference		Reference		Reference	
Quintile 5	1.07-2.56	258	39	64.3	**2.08 (1.42-3.03)**	**<.001**	**2.15 (1.52-3.04)**	**<.001**	**1.85 (1.30-2.62)**	**<.001**	**1.83 (1.28-2.63)**	**0.001**
First Cardiovascular Event or Any-Cause Death												
ADMA												
Quintile 1 to 4	0.43-1.06	951	506	260.5	Reference		Reference		Reference		Reference	
Quintile 5	1.07-2.56	235	138	337.5	**1.30 (1.07-1.57)**	**0.008**	**1.32 (1.09-1.60)**	**0.005**	**1.25 (1.03-1.53)**	**0.02**	**1.26 (1.03-1.54)**	**0.02**
Any-Cause Death												
ADMA												
Quintile 1 to 4	0.43-1.06	1018	438	163.7	Reference		Reference		Reference		Reference	
Quintile 5	1.07-2.56	258	127	209.4	**1.27 (1.04-1.56)**	**0.02**	**1.32 (1.11-1.58)**	**0.002**	**1.18 (1.01-1.39)**	**0.04**	1.18 (0.99-1.40)	0.06
First Infection-Related Hospitalization or Any-Cause Death												
Quintile 1 to 4	0.43-1.06	955	525	280.3	Reference		Reference		Reference		Reference	
Quintile 5	1.07-2.56	228	138	354.0	**1.26 (1.12-1.42)**	**<.001**	**1.28 (1.14-1.43)**	**<.001**	**1.19 (1.06-1.34)**	**0.004**	**1.18 (1.05-1.33)**	**0.005**

Abbreviation: IR, Incidence Rate; HR, Hazard Ratio; CI, Confidence Interval; ADMA, Asymmetric Dimethylarginine; SDMA, Symmetric Dimethylarginine
HR represents increase in risk per 2-fold increase in ADMA or SDMA concentrations. Modeled as natural log transformed variable/natural log of 2.
Model 1 was unadjusted.
Model 2 adjusted for age, sex and race.
Model 3 adjusted for variables in Model 2 + Index of Coexisting Disease (ICED) severity score, cause of end-stage renal disease, body mass index (categorized as <18, 18 to 25 and >25 kg/m2), systolic blood pressure (categorized as <130, 130-160 and >160 mm Hg), albumin, and relative volume removed on dialysis
Model 4 adjusted for variables in Model 3 + residual kidney function (urinary $stdKt/V_{UREA}$ calculated from urinary urea clearance).